<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Ab-Inbev on Bioecon</title><link>https://en.bioecon.ru/companies/ab-inbev/</link><description>Recent content in Ab-Inbev on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Sat, 11 Jul 2026 14:19:14 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/companies/ab-inbev/index.xml" rel="self" type="application/rss+xml"/><item><title>Brewing &amp; distillation as a fermentation platform</title><link>https://en.bioecon.ru/technology/brewing-distillation-as-fermentation-platform/</link><pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/brewing-distillation-as-fermentation-platform/</guid><description>Brewing and distillation capacity (250–500 m³ tanks) is being repurposed as a fermentation CDMO platform for recombinant proteins — from beer and spirits to collagen and albumin.</description></item></channel></rss>